Literature DB >> 15198664

In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats.

Sophie Sarre1, Hong Yuan, Nadine Jonkers, An Van Hemelrijck, Guy Ebinger, Yvette Michotte.   

Abstract

We investigated the effect of an injection of 6-hydroxydopamine (6-OHDA) into the rat medial forebrain bundle (MFB) on the degeneration and the function of the dopaminergic cell bodies in the substantia nigra (SN) 3 and 5 weeks after lesioning. After injection of 6-OHDA into the MFB a complete loss of dopamine content was apparent in the striatum 3 weeks after lesioning. In the SN the amount of tyrosine hydroxylase-immunoreactive dopamine cells decreased gradually, with a near-complete lesion (> 90%) obtained only after 5 weeks, indicating that neurodegeneration of the nigral cells was still ongoing when total dopamine denervation of the striatum had already been achieved. Baseline dialysate and extracellular dopamine levels in the SN, as determined by in vivo microdialysis, were not altered by the lesion. A combination of compensatory changes of the remaining neurones and dopamine originating from the ventral tegmental area may maintain extracellular dopamine at near-normal levels. In both intact and lesioned rats, the somatodendritic release was about 60% tetrodotoxin (TTX) dependent. Possibly two pools contribute to the basal dopamine levels in the SN: a fast sodium channel-dependent portion and a TTX-insensitive one originating from diffusion of dopamine. Amphetamine-evoked dopamine release and release after injection of the selective dopamine reuptake blocker GBR 12909 were attenuated after a near-complete denervation of the SN (5 weeks after lesioning). So, despite a 90% dopamine cell loss in the SN 5 weeks after an MFB lesion, extracellular dopamine levels in the SN are kept at near-normal levels. However, the response to a pharmacological challenge is severely disrupted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198664     DOI: 10.1111/j.1471-4159.2004.02471.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

2.  The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats.

Authors:  Zhijuan Mao; Chanchan Liu; Suqiong Ji; Qingmei Yang; Hongxiang Ye; Haiyan Han; Zheng Xue
Journal:  Neurochem Res       Date:  2017-02-28       Impact factor: 3.996

3.  The Effects of Crocin on 6-OHDA-Induced Oxidative/Nitrosative Damage and Motor Behaviour in Hemiparkinsonian Rats.

Authors:  Maryam Hosseini; Ziba Rajaei; Hojjatallah Alaei; Mohamadhasan Tajadini
Journal:  Malays J Med Sci       Date:  2016-12-07

4.  ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.

Authors:  Michael F Salvatore
Journal:  J Neurochem       Date:  2014-01-27       Impact factor: 5.372

Review 5.  Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.

Authors:  Mohamed El-Gamal; Mohamed Salama; Lyndsey E Collins-Praino; Irina Baetu; Ahmed M Fathalla; Amira M Soliman; Wael Mohamed; Ahmed A Moustafa
Journal:  Neurotox Res       Date:  2021-03-25       Impact factor: 3.911

Review 6.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

Review 7.  A guide to neurotoxic animal models of Parkinson's disease.

Authors:  Kim Tieu
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

8.  Decoding of dopaminergic mesolimbic activity and depressive behavior.

Authors:  Alexander Friedman; Ilana Deri; Yaakov Friedman; Eliyahu Dremencov; Sophia Goutkin; Elizabeth Kravchinsky; Matti Mintz; Dino Levi; David H Overstreet; Gal Yadid
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

9.  Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Chieh-Sen Chuang; Hong-Lin Su; Fu-Chou Cheng; Shan-hui Hsu; Chi-Fen Chuang; Chin-San Liu
Journal:  J Biomed Sci       Date:  2010-02-13       Impact factor: 8.410

Review 10.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.